Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2

Albert Cortés-Borra, Gonzalo Emiliano Aranda-Abreu, Albert Cortés-Borra, Gonzalo Emiliano Aranda-Abreu

Abstract

Background: Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies.

Methods: We searched in the PubMed database Clinical Studies of coronavirus-infected patients who have been treated with amantadine in a preventive manner as well as patients with Parkinson's disease.

Results: Four clinical studies were found in which relatives of patients with COVID-19 had been prescribed the use of amantadine in a preventive manner to avoid the symptoms caused by the coronavirus.

Conclusion: Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus.

Keywords: Amantadine; Prevention; SARS-CoV-2.

Conflict of interest statement

No conflict of interest.

References

    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta bio-medica: AteneiParmensis. 2020;91(1):157–160.
    1. RECOVERY CG, Horby P, Mafham M, Linsell L, Bell JL, Staplin N. EffEnect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030–2040. doi: 10.1056/NEJMoa2022926.
    1. Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann ClinMicrobiolAntimicrob. 2020;19(1):23.
    1. Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020;582(7813):469. doi: 10.1038/d41586-020-01824-5.
    1. Choi SW, Shin JS, Park SJ, Jung E, Park YG, Lee J. et al., Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res. 2020; p. 104955.
    1. Kim A, Gandhi R. Coronavirus disease 2019 (COVID-19): management in hospitalized adults. UpToDate. 2020.
    1. Dembitsky VM, Gloriozova TA, Poroikov VV. Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases. BiochemBiophys Res Commun. 2020;529(4):1225–1241. doi: 10.1016/j.bbrc.2020.06.123.
    1. McKimm-Breschkin JL, Fry AM. Meeting report: 4th ISIRV antiviral group conference: novel antiviral therapies for influenza and other respiratory viruses. Antivir Res. 2016;129:21–38. doi: 10.1016/j.antiviral.2016.01.012.
    1. Abreu GEA, Aguilar MEH, Covarrubias DH, Durán FR. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020;140:109755. doi: 10.1016/j.mehy.2020.109755.
    1. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R, Hernández-Aguilar ME, Herrera-Covarrubias D, Rojas-Durán F. Observational study of people infected with SARS-Cov-2, treated with amantadine. Pharmacol Rep. 2020;72(6):1538–1541. doi: 10.1007/s43440-020-00168-1.
    1. Cortés BA. Does amantadine have a protective effect against COVID-19. NeurolNeurochir Pol. 2020;54(3):284–285. doi: 10.5603/PJNNS.a2020.0041.
    1. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. MultSclerRelatDisord. 2020;42:102163.
    1. Aranda-Abreu GE, Aranda-Martínez JD, Araújo R. Use of amantadine in a patient with SARS-CoV-2. J Med Virol. 2020.
    1. Tipton PW, Wszolek ZK. What can Parkinson’s disease teach us about COVID-19. NeurolNeurochir Pol. 2020;54(2):204–206.
    1. Smieszek SP, Przychodzen BP, Polymeropoulos MH. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents. 2020;55(6):106004. doi: 10.1016/j.ijantimicag.2020.106004.
    1. Cimolai N. Potentially repurposing adamantanes for COVID-19. J Med Virol. 2020;92(6):531–532. doi: 10.1002/jmv.25752.
    1. Araújo R, Aranda-Martínez JD, Aranda-Abreu GE. Amantadine treatment for people with COVID-19. Arch Med Res. 2020;51(7):739–740. doi: 10.1016/j.arcmed.2020.06.009.
    1. Wiwanitkit V. Amantadine, COVID-19 and Parkinsonism. Arch Med Res. 2020;51(7):714. doi: 10.1016/j.arcmed.2020.07.001.
    1. Baig AM, Khaleeq A, Syeda H. Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2. ACS PharmacolTranslSci. 2020;3(6):1430–1433.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel